Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.

US FDA commissioner tells J.P. Morgan conference that the agency, industry, and the entire healthcare system need to change ‘at the same time’ in order for clinical trials to improve.

Michael Johnson previously was CEO from 2003 to 2017 and from 2019 to early 2020, as well as chairman from 2007 to early 2020. Direct seller granted him an equity-based long-term incentive plan in stock appreciation rights and restricted stock units.

Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.